Large Molecule API Sector Becomes Increasingly Crowded as Peregrine Changes Focus

by

Competition within the 2,000-5,000 L biomanufacturing segment is set to intensify as Peregrine Pharmaceuticals (Tustin, Calif., USA) announced its transition to a dedicated CDMO from an excess capacity player.

The company announced the move during the company’s quarterly conference call. Subsequently, Mark Bamforth, currently Brammer Bio (Lexington, Mass., USA) CEO and president, was appointed to the company’s board of directors. This followed appointment of Roger Lias, an experienced executive, as the new head of its CDMO division, Avid Bioservices (Tustin).

In reality, Peregrine is making virtue out of necessity as it readjusts after failure of its lead product bavituximab, which led to a 20% reduction in staff and the inevitable hit to the share price. The company has forecast flat revenues for fiscal 2018, with CMO revenues estimated to be around $50-$55 million, despite a bumper first quarter.

Avid Bioservices joins a roster of other CDMOs serving the clinical/early commercial biological segment.
These include…

This article is reprinted from the November issue of Bio/Pharmaceutical Outsourcing Report. For access to the full article and to learn more click here.

Related posts:
Bio/Pharma Financing and Drug Approvals Bounce Back in 2017
AMRI Sold to PE Firms
Growing Mexico Is Home to Solid CMO Population

Saul is PharmSource’s Director of Market Intelligence. He brings over 15 years of experience in market analysis, having worked in business intelligence roles at Evaluate Pharma, Cardinal Health (now Catalent) and Abbott Laboratories. Prior to that, he was a Post-doctoral fellow in Neuropharmacology at the Universities of Birmingham and Bristol.  Saul holds an MSc (Neuroscience) from the Institute of Psychiatry (King’s College London) and a D.Phil in Neuropharmacology from the University of Oxford.

More posts by Saul Richmond